SGO on Twitter: "Olaparib maintenance therapy improves overall survival in recurrent #ovariancancer - important update of the SOLO2 trial at #ASCO20 #SGOatASCO #gyncsm https://t.co/xX2D6nyErE" / Twitter
Study 19: final overall survival in all patients and according to BRCAm... | Download Scientific Diagram
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy | British Journal of Cancer
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial | International Journal of Gynecologic Cancer
Overall Survival Benefit is Seen with Olaparib in Patients with Ovarian Cancer and TP53 Disruptive Mutation Status | ESMO
Olaparib for Metastatic Breast Cancer | NEJM Resident 360 <meta property="twitter:image" content="https://resident360files.nejm.org/image/upload/c_fit,f_auto,h_120,w_120/v1538599218/u8buf4o8mgdxgmfcczjk.png" /> <meta property="og:image" content="https ...
3 Charts | Olaparib: A New Hope for BRCA Patients with Ovarian Cancer
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial - The Lancet Oncology
Olaparib Maintenance Therapy Delays Ovarian Cancer Progression - NCI
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG
Efficacy of LYNPARZA® (olaparib) from Study 19
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
Efficacy of LYNPARZA® (olaparib) for Maintenance in Recurrent Ovarian Cancer
SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer | Business Wire
Olaparib for Metastatic Castration-Resistant Prostate Cancer | NEJM
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial - Gynecologic Oncology
Lynparza extended survival of ovarian cancer patients' < Pharma < 기사본문 - KBR
PARP inhibitor (olaparib) dramaticalyl extends progression free survival in 1L Maintenance BRCAm ovarian cancer data. Hazard ratio = 0.30. : r/medicine
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer - Annals of Oncology
VisualAbstract: Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | 2 Minute Medicine
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy - European Journal of Cancer
